4.6 Article

Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE

Journal

BRITISH JOURNAL OF DERMATOLOGY
Volume 171, Issue 5, Pages 1091-1098

Publisher

WILEY-BLACKWELL
DOI: 10.1111/bjd.13137

Keywords

-

Categories

Funding

  1. University Medical Centre St Radboud Foundation
  2. Pfizer
  3. Janssen
  4. AbbVie

Ask authors/readers for more resources

Background Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life. Objectives To investigate to what extent treatment decisions made by dermatologists in daily clinical practice for patients with psoriasis on biologics are already in accordance with treatment goals without the active application of the treatment goals algorithm. Methods Data were extracted from a prospective daily practice cohort of patients with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). Treatment decisions such as dosage adjustments, combination treatments, or switching therapy were compared with the treatment goals algorithm. Results In 64% (253 of 395) of visits, physicians followed the treatment goals algorithm. There were 162 (41%) visits in which there should have been a treatment modification according to treatment goals (group Modify) and a modification was indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment modification was necessary (group Continue) and therapy was indeed not modified in 194 of 233 visits (83%). Conclusions Physicians acted in accordance with treatment goals in the majority of patient visits. In the patient group not achieving these goals, physicians should have modified therapy according to treatment goals but continued the same therapeutic regimen in the majority of visits. Optimizing therapy and defining barriers in the latter group might increase treatment results in daily practice psoriasis care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance Center

Linda Davidson, Juul M. P. A. Van den Reek, Florence Van Hunsel, Elke M. G. J. De Jong, Bart Jan Kullberg

Summary: This study analyzed spontaneous safety reports to identify associations between different biologics and bacterial skin or herpesvirus infections. The results showed that ustekinumab was strongly associated with bacterial skin infections, while infliximab showed the strongest association with herpes simplex and Epstein-Barr virus infections. All biologics were positively associated with bacterial skin infections, herpes simplex, and herpes zoster.

ACTA DERMATO-VENEREOLOGICA (2022)

Letter Dermatology

Optimizing shared decision making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic

M. E. C. van Winden, F. M. Klosters, M. Hamaker, M. G. Olde Rikkert, P. C. M. van de Kerkhof, E. M. G. J. de Jong, S. F. K. Lubeek

BRITISH JOURNAL OF DERMATOLOGY (2022)

Article Dermatology

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

Marloes. E. Van Muijen, Sarah E. Thomas, Hans M. M. Groenewoud, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Sharon R. P. Dodemont, Else N. Kop, Maartje A. M. Berends, Marjolein I. A. Koetsier, Johannes M. Mommers, John E. M. Korver, Ron A. Tupker, Marjolein S. De Bruin-Weller, Lizelotte J. M. T. Weppner-Parren, Bas Peters, Marloes M. Kleinpenning, Astrid L. A. Kuijpers, W. Peter Arnold, Paula P. M. Van Lumig, Juul M. P. A. Van den Reek, Elke M. G. J. De Jong

Summary: Real-world evidence comparing the effectiveness of different biologic therapies for psoriasis shows that adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab are more effective in reducing PASI scores and achieving PASI90 than etanercept. Ixekizumab and guselkumab have higher probabilities of achieving PASI90 than other treatments. The proportions of patients reaching PASI90/75 are lower in real-world studies compared to randomized controlled trials.

ACTA DERMATO-VENEREOLOGICA (2022)

Article Dermatology

Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy - a mixed-method pilot study

Elke L. M. ter Haar, Marcia Tummers, Ewald M. Bronkhorst, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong, Satish F. K. Lubeek

Summary: There is sparse evidence-based guidance for psoriasis treatment in older adults, leading to potential undertreatment. A survey and interviews with dermatologists in the Netherlands revealed age-based treatment differences and some reluctance to prescribe systemic therapy in older adults. Comorbidity, comedication, and fear of adverse events were identified as the main reasons for these differences. The study highlights the need for more evidence-based guidance, education, and consultation time to improve treatment in the growing population of older adults with psoriasis.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Article Dermatology

Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study

Elke L. M. Ter Haar, Eline E. Ten Bruin, Ewald M. Bronkhorst, Rinke J. Borgonjen, Marloes M. Kleinpenning, Else N. Kop, M. Birgitte Visch, Peter C. M. Van De Kerkhof, Elke M. G. J. De Jong, Satish F. K. Lubeek

Summary: This multicentre retrospective study examined the safety of systemic therapy in older adults with psoriasis and analyzed predictors for adverse events. The study found that increasing age was associated with a higher incidence of adverse events, while comorbidity, polypharmacy, and treatment type were not related to adverse event occurrence. Causality assessment showed that serious adverse events were rare and manageable in clinical practice, indicating a reassuring safety profile for systemic antipsoriatic therapy in this population.

ACTA DERMATO-VENEREOLOGICA (2022)

Article Dermatology

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe

Summary: The study aimed to estimate the prevalence of SARS-CoV-2 infection in psoriasis patients, compare infection rates among different treatment groups, and describe severe COVID-19 cases. The findings suggest that the risk of SARS-CoV-2 infection is not increased for psoriasis patients using biologics or non-biologic systemic therapy compared to other treatments.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Article Dermatology

Development of a New Referral Tool to Identify Psoriasis Patients with Concomitant Psoriatic Arthritis: Results of the Prospective DAPPER Cohort

Tamara W. Van Hal, Michelle L. M. Mulder, Mark H. Wenink, Frank H. J. Van Den Hoogen, Jake S. F. Maurits, Marcel C. Pasch, Juul M. P. A. Van Den Reek, Elke M. G. J. De Jong

Summary: In this study, researchers used data from the DAPPER study to identify predictive variables for concomitant psoriatic arthritis and created a referral tool based on these variables, with an area under the curve of 0.82. This referral tool could assist dermatologists in identifying psoriasis patients with concomitant psoriatic arthritis.

ACTA DERMATO-VENEREOLOGICA (2023)

Article Dermatology

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice

L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong

Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Letter Dermatology

Identification of children at risk for the development of severe paediatric plaque psoriasis: Findings from the prospective observational long-term Child-CAPTURE registry

Inge M. G. J. Bronckers, Elke M. G. J. de Jong, Celia A. J. Michielsens, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Marieke M. B. Seyger

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial

Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn, Phyllis I. Spuls

Summary: This study compared the long-term effectiveness and safety of the combination of methotrexate and adalimumab with adalimumab monotherapy in patients with moderate to severe plaque type psoriasis. The results showed a trend towards longer drug survival in the combination therapy group, but no significant difference was found compared to the monotherapy group. Similar conclusions were drawn regarding the efficacy, safety, pharmacokinetics, and immunogenicity of the drugs. Overall, combination therapy may have a better effect in individual patients.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Editorial Material Dermatology

How to define a super-responder' to biologics in psoriasis studies

Sarah E. Thomas, Juul M. P. A. Van den Reek, Marieke M. B. Seyger, Elke M. G. J. de Jong

Summary: In this study, the researchers aimed to synthesize the various definitions of super-responders in psoriasis literature and evaluate their impact on the composition of the super-responder group.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Editorial Material Dermatology

Should we prefer biologics over nonbiological agents in psoriasis?

Sarah E. Thomas, Juul M. P. A. Van den Reek

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Patients' perspectives towards biologic dose reduction in psoriasis: a qualitative study

L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek

Summary: This study aimed to explore patients' perspectives towards dose reduction of biologics for psoriasis. Patients perceived benefits of dose reduction including minimizing medication use, lowering risks of adverse effects, and lowering healthcare costs. However, they also expressed concerns about the potential loss of disease control. Addressing patients' concerns, fulfilling information needs, providing the possibility of resuming standard dose, and involving patients in decision-making are important when considering biologic dose reduction.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

No Data Available